Browse Drug Recalls
17,874 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 17,874 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 17,874 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Jan 14, 2020 | Testosterone Cypionate for Injection, 2,000 mg/10 mL (200 mg/mL), a) 1 mL Sin... | cGMP Deviations; released lots were manufactured under similar manufacturing conditions to a prev... | Class II | Sun Pharmaceutical Industries, Inc. |
| Jan 10, 2020 | NETSPOT, (kit for the preparation of Ga 68 dotatate injection) 40 mcg dotatat... | Defective Container: loose aluminum cap crimp for the dilution buffer vial present in the NETSPOT... | Class II | Advanced Accelerator Applications USA, Inc. |
| Jan 10, 2020 | ranitidine hydrochloride, USP ,150 mg tablets a) 14-count bottles ( NDC 430... | CGMP Deviations: Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts ... | Class II | PD-Rx Pharmaceuticals, Inc. |
| Jan 10, 2020 | Estriol USP Micronized a) 100 gm NDC 62991-2159-04; b) 1 gm NDC 62991-2159-01... | Subpotent | Class II | Letco Medical LLC |
| Jan 10, 2020 | Tri-Lo-Marzia (Norgestimate and Ethinyl Estradiol Tablets, USP), 0.180 mg/0.0... | CGMP Deviations: Out of specification test result observed during retrospective review of blend u... | Class III | Lupin Pharmaceuticals Inc. |
| Jan 7, 2020 | Dutasteride Capsules, 0.5 mg, 30 Capsules (6 X 5) Unit Dose per carton, Rx On... | Failed Impurities/Degradation Specifications: High out of specification results for related compo... | Class II | AVKARE Inc. |
| Jan 7, 2020 | Eczema Skin Relief Lotion, 2% Colloidal Oatmeal Skin Protectant Lotion, NET W... | Microbial contamination of non-sterile product. | Class III | Sigan Industries Inc. |
| Jan 7, 2020 | Nizatidine Capsules, USP 150 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 037... | CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the ... | Class II | Mylan Pharmaceuticals Inc. |
| Jan 7, 2020 | Ranitidine Capsules 300 mg, 30 count bottles. Rx only, Manufactured by: Appco... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Appco Pharma LLC |
| Jan 7, 2020 | Nizatidine Capsules, USP 300 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 037... | CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the ... | Class II | Mylan Pharmaceuticals Inc. |
| Jan 7, 2020 | Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 300 mg, Rx Only, a) 14 co... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Preferred Pharmaceuticals, Inc |
| Jan 7, 2020 | Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottl... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Preferred Pharmaceuticals, Inc |
| Jan 7, 2020 | Ranitidine Capsules 150 mg, (a) 60 count bottles (NDC 62559-690-60) , (b) 500... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Appco Pharma LLC |
| Jan 6, 2020 | Ranitidine, 150 mg Tablets, a) 7 count, b) 14 count, c) 20 count, d) 30 count... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | H J Harkins Company Inc dba Pharma Pac |
| Dec 27, 2019 | Ketorolac Trom, 30 mg/1mL Inj. for I.V./I.M. Use, Rx Only, QTY: 1 ml, Repacka... | Presence of Particulate Matter: Medication relabeled at facility was recalled by the manufacturer... | Class I | RemedyRepack Inc. |
| Dec 26, 2019 | Ranitidine 150 mg tablets, 130 count bottles, NDC 37808-196-04. | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | AAA Pharmaceutical, Inc. |
| Dec 26, 2019 | Blisovi Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets USP a... | Failed Tablet/Capsule Specifications: Complaints related to crumbling of tablets when popped out ... | Class II | Lupin Pharmaceuticals Inc. |
| Dec 26, 2019 | Sumatriptan Succinate Tablets, 50 mg, packaged in a) 9 (1x9) Unit-of use blis... | Failed Impurities/Degradation Specifications; out-of-specification results obtained for related s... | Class II | Sun Pharmaceutical Industries, Inc. |
| Dec 26, 2019 | Sumatriptan Succinate Tablets, 100 mg packaged in 9 (1X9) Unit-of-use bliste... | Failed Impurities/Degradation Specifications; out-of-specification results obtained for related s... | Class II | Sun Pharmaceutical Industries, Inc. |
| Dec 26, 2019 | Proparacaine Hydrochloride Ophthalmic Solution, USP, 0.5%, 15 mL per dropper ... | Chemical contamination; out of specification results obtained for equipment cleaning residue rins... | Class III | Akorn, Inc. |
| Dec 26, 2019 | Ranitidine 150 mg tablets, 24 count bottles, NDC 37808-196-01. | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | AAA Pharmaceutical, Inc. |
| Dec 23, 2019 | Theraflu Cough Relief, Dextromethorphan HBr and Guaifensin, 6 packets per car... | Labeling: Label Lacks Warning: Product recalled due to absence of a warning statement on the prod... | Class II | GSK Consumer Health, Inc |
| Dec 20, 2019 | BAC 50MCG/ HYDROM 10MG/ML INJ in 20 mL syringe Assurance Infusion (713) 53... | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | BUP 8MG/CLON 100MCG/HYDROM 20MG/ML INJ in 20 mL syringe Assurance Infusion (... | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | BAC 150 mcg/BUP 2 mg/Hydrom 15 mg/Morp 20 mg/SUF 650 mcg/mL Inj. in 20 mL syr... | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | BUP 40MG/MORP 4MG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | HYDROMORPHONE 15MG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | BUP 5MG/MORP 20MG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | BUP 30MG/FENT 750MCG/HYDROM 15MG/ML (40) INJ in 20 mL syringe Assurance Infu... | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | BUP 4MG/FENT 3000MCG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | MORPHINE 18MG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | MORPHINE 2MG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | Ranitidine Tablets, USP 300 mg a). 15-count bottles (NDC 70934-287-15), b). 9... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Denton Pharma, Inc. |
| Dec 20, 2019 | SUFENTANIL 150MCG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | MORP 20MG/SUF 70MCG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | HCG 1,000U/1ML INJ in 4 mL vial Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | BAC 400MCG/BUP 20MG/HYDROM 15MG/SUF 1000MCG/ML INJ in 20 mL syringe Assuranc... | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | FENTANYL 3000MCG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | PCA Skin Blemish Control Bar, 3.2 oz/90g, Salicylic acid 2% - Acne cleanser, ... | Superpotent Drug: Salicylic acid content is above the firm's specification. | Class III | Island Kinetics, Inc. d.b.a. CoValence Laborato... |
| Dec 20, 2019 | QUADMIX 30MG/2MG/20MCG/100MCG/ML INJ in 1 mL vial Assurance Infusion (713) 5... | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | BUP 10MG/HYDROM 10MG/MORP 2MG/SUF 250MCG/ML INJ in 20 mL syringe Assurance I... | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | Alprostadil 40 mcg/mL (2 mL vial) Inj. Soln. in 2 mL vials Assurance Infusion... | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | MORPHINE 10MG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | TRIMIX 30MG/1MG/10MCG/ML INJ in 5 mL/10 mL vials Assurance Infusion (713) 5... | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | MORPHINE 7MG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | Bi-Mix Forte 30 mg/2 mg/mL Inj. in 1 mL vials Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | FENTANYL 2000MCG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | BUP 7MG/HYDROM 20MG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | BUP 15MG/CLON 600MCG/MORP 30MG/ML (40) INJ in 20 mL syringe Assurance Infusi... | Lack of sterility assurance. | Class II | Assurance Infusion |
| Dec 20, 2019 | BUP 3 mg/MORP 15 mg/mL Inj. in 20 mL syringe Assurance Infusion (713) 533-8800 | Lack of sterility assurance. | Class II | Assurance Infusion |
Frequently Asked Questions
When a drug safety issue is identified, through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks, the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.